Evidence map›Paper›PMID 40124383›Full record

ArticleFrontiers in immunology2025

Effective long-term treatment with moss-produced factor H by overcoming the antibody response in a mouse model of C3G.

Todor Tschongov, Swagata Konwar, Jessika Kleindienst, Paulina Dabrowska-Schlepp, Andreas Busch, Andreas Schaaf, Christoph Schell, Manuel Rogg, Karsten Häffner

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Todor TschongovDepartment of Internal Medicine IV, Medical Faculty, University of Freiburg, Freiburg, Germany.
Swagata KonwarDepartment of Internal Medicine IV, Medical Faculty, University of Freiburg, Freiburg, Germany.
Jessika KleindienstDepartment of Internal Medicine IV, Medical Faculty, University of Freiburg, Freiburg, Germany.
Paulina Dabrowska-SchleppNonclinical Development, Eleva GmbH, Freiburg, Germany.
Andreas BuschNonclinical Development, Eleva GmbH, Freiburg, Germany.
Andreas SchaafNonclinical Development, Eleva GmbH, Freiburg, Germany.
Christoph SchellInstitute for Surgical Pathology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Manuel RoggInstitute for Surgical Pathology, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Karsten HäffnerDepartment of Internal Medicine IV, Medical Faculty, University of Freiburg, Freiburg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Complement-associated disorders are caused by the dysregulation and disbalance of the complement system, especially excessive activation. Most drugs that target the complement system are designed to inhibit the complement pathway at either the proximal or terminal levels. The use of a natural complement regulator such as factor H (FH) could provide a superior treatment option by restoring balance to an overactive complement system. We recently reported the moss-based production of an analog of human FH with an optimized glycan profile (CPV-104), which showed

Indexed as

Antibody FormationComplement Factor HAnimalsB-LymphocytesCD4-Positive T-LymphocytesComplement C3Disease Models, AnimalHumansMiceMice, Inbred C57BLMice, KnockoutComplement C3Complement Factor Hanti-drug antibodiesB-cell depletionC3 glomerulopathycomplement factor Hcomplement systemprotein replacement therapyT-cell depletion

Identifiers

PMID40124383
PMCPMC11925764

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.